Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
…
51,083$
0,10%
Echtzeit-Aktienkurs Rhythm Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Rhythm Pharmaceuticals Inc. Aktie
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals CTO sells shares worth over $735k By Investing.com
Rhythm Pharmaceuticals CTO sells shares worth over $735k…
Rhythm Pharmaceuticals executive sells shares worth over $700k By Investing.com
Rhythm Pharmaceuticals executive sells shares worth over $700k…
Rhythm Pharmaceuticals CFO sells shares worth over $600k By Investing.com
Rhythm Pharmaceuticals CFO sells shares worth over $600k…
Rhythm Pharmaceuticals exec sells $627,520 in stock By Investing.com
Rhythm Pharmaceuticals exec sells $627,520 in stock…
Earnings call: Rhythm Pharmaceuticals reports transformative year, eyes 2025 By Investing.com
Earnings call: Rhythm Pharmaceuticals reports transformative year, eyes 2025…
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript
…
Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation
…
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Insiderhandel: EVP, Head of North America verkauft Aktien von Rhythm Pharmaceuticals im Wert von 42.366$
Lee, Jennifer Kayden - Vorstand - Tag der Transaktion: 2023-08-09...…
Insiderhandel: EVP, Head of North America verkauft Aktien von Rhythm Pharmaceuticals im Wert von 271.347$
Lee, Jennifer Kayden - Vorstand - Tag der Transaktion: 2023-08-07...…
Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Form 8-K RHYTHM PHARMACEUTICALS, For: Jul 28
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharma surges on strong Q2 sales; BofA upgrades
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Shares Jump After 2Q Revenue Tops Expectations
Rhythm Pharmaceuticals Shares Jump After 2Q Revenue Tops Expectations...…
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -2.50% and 29.96%, respectively, for the quarter ended June 2023.…
Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, revenue of $19.2M beats by $4.17M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, revenue of $19.22M beats by $4.19M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Human Resources Officer verkauft Aktien von Rhythm Pharmaceuticals im Wert von 16.405$
Cramer, Pamela J. - Vorstand - Tag der Transaktion: 2023-07-26...…
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Form 8-K RHYTHM PHARMACEUTICALS, For: Jun 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean…
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Form 10-Q RHYTHM PHARMACEUTICALS, For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -29.58% and 2.71%, respectively, for the quarter ended March 2023.…
Rhythm Pharmaceuticals reports misses Q1 top and bottom consensus; reaffirms FY23 outlook
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
-- Strong U.S. commercial progress continues for IMCIVREE® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received…
Form 8-K RHYTHM PHARMACEUTICALS, For: May 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
IMCIVREE is eligible for federal reimbursement by Statutory Health Insurances in Germany IMCIVREE is eligible for federal reimbursement by Statutory…
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…